New drug aims to strengthen bones in people with brittle bone disease
Disease control
Not yet recruiting
This study tests a new medicine called AGA2115 in 48 Chinese adults and teenagers with osteogenesis imperfecta (brittle bone disease) types I, III, or IV. The goal is to see if different doses are safe and can improve bone density. Participants will receive one of three dose sche…
Phase: PHASE2 • Sponsor: Angitia Biopharmaceuticals Guangzhou Limited • Aim: Disease control
Last updated May 09, 2026 04:35 UTC